Bevacizumab therapy in patients with recurrent uterine neoplasms

Anticancer Research

Volumn 27, Issue 5 B, 2007, Pages 3525-3528

  Wright, Jason D ^a   Powell, Matthew A ^b   Rader, Janet S ^b   Mutch, David G ^b   Gibb, Randall K ^c  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c BILLINGS CLINIC   (United States)

Author keywords

Angiogenesis; Bevacizumab; Endometrial cancer; Uterine cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER STAGING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FATIGUE; HUMAN; HYPERTENSION; LEIOMYOSARCOMA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; THROMBOCYTOPENIA; THROMBOSIS; UTERUS CANCER;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DEMOGRAPHY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; UTERINE NEOPLASMS;

EID: 35348985425     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55(1): 10-30, 2005.
2. Aalders JG, Abeler V and Kolstad P: Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 17(1): 85-103, 1984.
3. Burke TW, Heller PB, Woodward JE, Davidson SA, Hoskins WJ and Park RC: Treatment failure in endometrial carcinoma. Obstet Gynecol 75(1): 96-101, 1990.
4. Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, Umemoto M and Saito Y: Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 77(3): 413-418, 2000.
5. Obermair A, Tempfer C, Wasicky R, Kaider A, Hefler L and Kainz C: Prognostic significance of tumor angiogenesis in endometrial cancer. Obstet Gynecol 93(3): 367-371, 1999.
6. Lee CN, Cheng WF, Chen CA, Chu JS, Hsieh CY and Hsieh FJ: Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet Gynecol 96(4): 615-621, 2000.
7. Salvesen HB, Iversen OE and Akslen LA: Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17(5): 1382-1390, 1999.
8. Abulafia O, Triest WE, Sherer DM, Hansen CC and Ghezzi F: Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 86(4 Pt 1): 479-485, 1995.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342, 2004.
10. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5): 427-434, 2003.
11. Holland CM, Day K, Evans A and Smith SK: Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 89(5): 891-898, 2003.
12. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A and Burks RT: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22(11): 2159-2166, 2004.
13. Kanjeekal S, Chambers A, Fung MF and Verma S: Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 97(2): 624-637, 2005.
14. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT and Zaino RJ: A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52(4): 626-632, 1983.
15. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R and Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20(12): 2824-2831, 2002.